A Phase 2 interventional study of Rivoceranib in Adenoid Cystic Carcinoma, sponsored by Elevar Therapeutics. Terminated at 11 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-30.
Sponsored by Elevar Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies in Carcinoma, Adenoid Cystic with a site in United States — 11 open to participants now, 21 under way, none of them phase 3. Carcinoma, Adenoid Cystic · United States.
Among the 45 studies in Carcinoma, Adenoid Cystic with a site in United States, this one is the 13th largest by enrollment of the 43 interventional ones that give a count, is one of 4 that started in 2020, is one of 23 in phase 2, and was the 22nd registered.
86 studies on the registry are indexed under Carcinoma, Adenoid Cystic; 26 are open to participants now.
Browse Carcinoma, Adenoid Cystic studies →11 of the 45 studies in Carcinoma, Adenoid Cystic with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Dana-Farber Cancer Institute · Sites in United States
Ages 18+
Novelty Nobility, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 23 Carcinoma, Adenoid Cystic studies recruiting now, 15 (65%) set no upper age limit and 3 (13%) stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 31
First in 2007; this study’s year is marked. 4 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 80 is above the median of 37 across 76 interventional studies indexed under Carcinoma, Adenoid Cystic.
Median enrollment 38 across the 43 interventional studies, 107 across the 2 observational. Of the 23 that completed or were terminated, 14 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 45 have an industry lead sponsor. The 10 most frequent:
Elevar Therapeutics is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.
Elevar Therapeutics has 1 study filed under Carcinoma, Adenoid Cystic — fewer than ten, so there is no comparison to draw.
9 of the studies in Carcinoma, Adenoid Cystic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04209660Memorial Sloan Kettering Cancer CenterLenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers | 2026-12 |
| NCT04140526OncoC4, Inc.Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | 2026-12-31 |
| NCT05377996Day One Biopharmaceuticals, Inc.A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors | 2027-02 |
| NCT06891560Memorial Sloan Kettering Cancer CenterA Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma | 2027-03 |
| NCT02780310Memorial Sloan Kettering Cancer CenterTesting Lenvatinib in Patients With Adenoid Cystic Carcinoma | 2027-05 |
Add all 9 to your calendar (.ics) → With an account.
Among the 45 studies in Carcinoma, Adenoid Cystic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of rivoceranib in adult participants with recurrent or metastatic ACC. All participants may remain on treatment until occurrence of disease progression, unacceptable toxicity, death, the withdrawal of consent from treatment, lost to follow-up or study termination by the Sponsor. When a participant discontinues rivoceranib for any reason, the participant will enter the 24 month survival follow up period until withdrawal of consent from the study, lost to follow up, end of the study or death, whichever occurs earlier.
The maximum duration of the study is estimated to be 48 months and includes screening, treatment, and follow-up phases.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Evidence of disease progression by v1.1
Note: Disease progression is defined as one of the following occurring within the 6 months prior to study entry:
Participants are eligible if central nervous system (CNS) metastases have been treated and participants are neurologically returned to baseline or neurologically stable in the opinion of Investigator (except for residual signs or symptoms related to the CNS treatment) for at least 4 weeks prior to first dose of study drug administration. In addition, participants must be either off , or on a stable dose or decreasing dose of \<20 milligrams (mg) daily prednisone or prednisone equivalent.
Note: Only participants with a known history or indication of CNS disease are required to have CNS imaging prior to study entry
Adequate organ and marrow function within 14 days prior to the first dose of rivoceranib administration, defined as:
Exclusion Criteria:
History of another within 3 years prior to enrollment. A participant with the following malignancies is eligible for this study if, surgically and medically treated and in the opinion of the investigator, they do not pose a significant risk to or not likely to recur within 3 years:
An uncontrolled intercurrent illness including, but not limited to any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive an oral dose of rivoceranib once per day during 28-day cycles.
Drug: Rivoceranib
Film-coated tablets
Also known as: Apatinib, Apatinib Mesylate
Objective Response Rate (ORR): Percentage of Participants Who Achieved Confirmed Complete Response (CR) or Partial Response (PR) Per the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by Investigator/Institutional Assessment
Complete Response - Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeters (mm) (the sum may not be "0" if there are target nodes). Partial Response - At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: Up to 41 months
ORR: Percentage of Participants Who Achieve Confirmed CR or PR Per RECIST 1.1 by Independent Central Review
CR - Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm (the sum may not be "0" if there are target nodes). PR - At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: Up to 41 months
Overall Survival (OS) Rate
OS was defined as the interval from the start of study therapy to death from any cause. Here, the percentage of participants with OS at specified time points are shown.
Time frame: Months 12 and 24
Progression Free Survival (PFS) Rate at 6 Months, 12 Months, and 2 Years by Investigator or Institutional Assessment
PFS was defined as the time from the start of treatment with rivoceranib to the first evaluation showing Progressive Disease (PD) or death, whichever occurred first. Participants who did not experience PD or death were censored at the date of last disease assessment. Here, the percentage of participants with PFS at the given timepoints is shown. PD - At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression.)
Time frame: Months 6, 12, and 24
Progression Free Survival (PFS) at 6 Months, 12 Months, and 2 Years Evaluated by Independent Central Review
PFS was defined as the time from the start of treatment with rivoceranib to the first evaluation showing PD or death, whichever occured first. Participants who do not experience PD or death were censored at the date of last disease assessment. Here, the percentage of participants with PFS at the given timepoints is shown. PD - At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression.)
Time frame: Months 6 and 12, and Year 2
Duration of Response (DoR) Per RECIST Version 1.1 by Investigator or Institutional Assessment
Duration of response was the time from the first response of PR or CR (which was subsequently confirmed) to the first evaluation showing PD or death, whichever occurred first. Death due to any cause was considered in the determination of DOR. CR - Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm (the sum may not be "0" if there are target nodes). PR - At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. PD - At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression.)
Time frame: Up to 41 months
Duration of Response (DoR) Per RECIST Version 1.1 Evaluated by Independent Central Review
Duration of response was the time from the first response of PR or CR (which was subsequently confirmed) to the first evaluation showing PD or death, whichever occurred first. Death due to any cause was considered in the determination of DOR. CR - Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm (the sum may not be "0" if there are target nodes). PR - At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. PD - At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression.)
Time frame: Up to 41 months
Time to Progression (TTP) Per RECIST Version 1.1 by Investigator or Institutional Assessment
TTP was the length of time from the start of treatment with rivoceranib until objective tumor progression. At the time of analysis of TTP, any participants who do not experience PD including participants who died without PD were censored at the date of last disease assessment. The TTP was estimated using the Kaplan-Meier method. PD - At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression.)
Time frame: Up to 41 months
TTP Per RECIST Version 1.1 Evaluated by Independent Central Review
TTP was the length of time from the start of treatment with rivoceranib until objective tumor progression. At the time of analysis of TTP, any participants who do not experience PD including participants who died without PD were censored at the date of last disease assessment. The TTP was estimated using the Kaplan-Meier method. PD - At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression.)
Time frame: Up to 41 months
Number of Participants With Treatment-Emergent Adverse Events (AEs)
An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A summary of non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.
Time frame: From first dose of rivoceranib until 30 days after the last dose date of rivoceranib or initiation of other anticancer therapy, whichever is earlier (up to 41 months)
| Milestone | Rivoceranib |
|---|---|
| Started | 80 |
| Received at least 1 dose of study drug | 80 |
| Completed | 0 |
| Not completed | 80 |
| Withdrew: Death | 44 |
| Withdrew: Withdrawal by subject | 10 |
| Withdrew: Study terminated by sponsor | 12 |
| Withdrew: Other reasons | 14 |
Complete Response - Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeters (mm) (the sum may not be "0" if there are target nodes). Partial Response - At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.
| percentage of participants | Rivoceranib |
|---|---|
| Objective Response Rate (ORR): Percentage of Participants Who Achieved Confirmed Complete Response (CR) or Partial Response (PR) Per the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by Investigator/Institutional Assessment | 13.8 (7.1 to 23.3) |
CR - Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm (the sum may not be "0" if there are target nodes). PR - At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.
| percentage of participants | Rivoceranib |
|---|---|
| ORR: Percentage of Participants Who Achieve Confirmed CR or PR Per RECIST 1.1 by Independent Central Review | 8.8 (3.6 to 17.2) |
OS was defined as the interval from the start of study therapy to death from any cause. Here, the percentage of participants with OS at specified time points are shown.
| percentage of participants | Rivoceranib |
|---|---|
| Month 12 | 74.7 (62.9 to 83.3) |
| Month 24 | 51.5 (39.2 to 62.4) |
PFS was defined as the time from the start of treatment with rivoceranib to the first evaluation showing Progressive Disease (PD) or death, whichever occurred first. Participants who did not experience PD or death were censored at the date of last disease assessment. Here, the percentage of participants with PFS at the given timepoints is shown. PD - At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression.)
| percentage of participants | Rivoceranib |
|---|---|
| Month 6 | 74.1 (62.1 to 82.9) |
| Month 12 | 37.3 (22.5 to 49.0) |
| Month 24 | 8.9 (3.3 to 17.9) |
PFS was defined as the time from the start of treatment with rivoceranib to the first evaluation showing PD or death, whichever occured first. Participants who do not experience PD or death were censored at the date of last disease assessment. Here, the percentage of participants with PFS at the given timepoints is shown. PD - At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression.)
| percentage of participants | Rivoceranib |
|---|---|
| Month 6 | 78.3 (66.0 to 86.6) |
| Month 12 | 37.4 (24.6 to 50.2) |
Duration of response was the time from the first response of PR or CR (which was subsequently confirmed) to the first evaluation showing PD or death, whichever occurred first. Death due to any cause was considered in the determination of DOR. CR - Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm (the sum may not be "0" if there are target nodes). PR - At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. PD - At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression.)
| months | Rivoceranib |
|---|---|
| Duration of Response (DoR) Per RECIST Version 1.1 by Investigator or Institutional Assessment | 14.9 (4.9 to NA) |
Duration of response was the time from the first response of PR or CR (which was subsequently confirmed) to the first evaluation showing PD or death, whichever occurred first. Death due to any cause was considered in the determination of DOR. CR - Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm (the sum may not be "0" if there are target nodes). PR - At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. PD - At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression.)
| months | Rivoceranib |
|---|---|
| Duration of Response (DoR) Per RECIST Version 1.1 Evaluated by Independent Central Review | 7.2 (3.5 to 8.4) |
TTP was the length of time from the start of treatment with rivoceranib until objective tumor progression. At the time of analysis of TTP, any participants who do not experience PD including participants who died without PD were censored at the date of last disease assessment. The TTP was estimated using the Kaplan-Meier method. PD - At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression.)
| months | Rivoceranib |
|---|---|
| Time to Progression (TTP) Per RECIST Version 1.1 by Investigator or Institutional Assessment | 9.2 (8.5 to 13.7) |
TTP was the length of time from the start of treatment with rivoceranib until objective tumor progression. At the time of analysis of TTP, any participants who do not experience PD including participants who died without PD were censored at the date of last disease assessment. The TTP was estimated using the Kaplan-Meier method. PD - At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression.)
| months | Rivoceranib |
|---|---|
| TTP Per RECIST Version 1.1 Evaluated by Independent Central Review | 9.3 (8.5 to 13.6) |
An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A summary of non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.
| Participants | Rivoceranib |
|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (AEs) | 80 |
Collected over From first dose of rivoceranib until 30 days after the last dose date of rivoceranib or initiation of other anticancer therapy, whichever is earlier (up to 41 months). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rivoceranib | 44/80 (55%) | 32/80 (40%) | 80/80 (100%) |
| Event | Rivoceranib |
|---|---|
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 4/80 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 3/80 |
| PneumoniaInfections and infestations | 3/80 |
| Back painMusculoskeletal and connective tissue disorders | 3/80 |
| StomatitisGastrointestinal disorders | 2/80 |
| FatigueGeneral disorders | 2/80 |
| Non-cardiac chest painGeneral disorders | 2/80 |
| Decreased appetiteMetabolism and nutrition disorders | 2/80 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 1/80 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/80 |
| Event | Rivoceranib |
|---|---|
| HypertensionVascular disorders | 53/80 |
| FatigueGeneral disorders | 49/80 |
| NauseaGastrointestinal disorders | 43/80 |
| HeadacheNervous system disorders | 42/80 |
| StomatitisGastrointestinal disorders | 40/80 |
| DiarrhoeaGastrointestinal disorders | 35/80 |
| ProteinuriaRenal and urinary disorders | 32/80 |
| Decreased appetiteMetabolism and nutrition disorders | 30/80 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 27/80 |
| ConstipationGastrointestinal disorders | 25/80 |
The Safety Population included all enrolled participants who received at least 1 dose of study drug
| Age, Continuous(years) | Rivoceranib |
|---|---|
| Mean | 53.5 ± 11.78 |
| Sex: Female, Male(Participants) | Rivoceranib |
|---|---|
| Female | 38 |
| Male | 42 |
| Ethnicity (NIH/OMB)(Participants) | Rivoceranib |
|---|---|
| Hispanic or Latino | 7 |
| Not Hispanic or Latino | 72 |
| Unknown or Not Reported | 1 |
| Race (NIH/OMB)(Participants) | Rivoceranib |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 28 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 2 |
| White | 47 |
| More than one race | 3 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2020 to primary completion in Jun 2023, 41 months.
Results were first posted in Jul 2026, 3 years 1 month after primary completion. A results delay was requested in Jun 2024.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apatinib
Elevar Therapeutics